CliffBio
small molecule

SITAVIG

ACYCLOVIR

Loss of exclusivityJune 2030latest FDA-listed patent expiry
CompanyLigand Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameSITAVIG
Active ingredientACYCLOVIR
Strength50MG
Dosage formTABLET
RouteBUCCAL
ModalitySmall molecule
FDA approvalApril 2013
Marketing statusDISCN

Listed patents

PatentExpiresType
8592434June 2030product
8747896June 2027product
8791127March 2027product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

SITAVIG patent cliff — loss of exclusivity June 2030 | CliffBio